A5044221282- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Global Cancer Incidence and Screening
- Advanced Radiotherapy Techniques
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- Bladder and Urothelial Cancer Treatments
- Hormonal and reproductive studies
- Family Support in Illness
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Screening and Detection
- Pancreatitis Pathology and Treatment
- Pancreatic and Hepatic Oncology Research
- Migration, Health and Trauma
- Nutrition and Health in Aging
- Health Literacy and Information Accessibility
- Advances in Oncology and Radiotherapy
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Neuroendocrine Tumor Research Advances
- Gastric Cancer Management and Outcomes
- Cancer Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Palliative Care and End-of-Life Issues
Kaiser Permanente
2022-2025
Dana-Farber Brigham Cancer Center
2015-2023
Brigham and Women's Hospital
2015-2023
Harvard University
2015-2023
Dana-Farber Cancer Institute
2015-2023
Kaiser Permanente Center for Health Research
2022
Chettinad Health City
2021
Tohoku University
2020
Radiation Oncology Associates
2020
Hudson Institute
2020
Purpose Androgen deprivation therapy (ADT) may contribute to depression, yet several studies have not demonstrated a link. We aimed determine whether receipt of any ADT or longer duration for prostate cancer (PCa) is associated with an increased risk depression. Methods identified 78,552 men older than age 65 years stage I III PCa using the SEER-Medicare–linked database from 1992 2006, excluding patients psychiatric diagnoses within prior year. Our primary analysis was association between...
We determined the incidence of pathological upgrading and up staging for contemporary, clinically low risk patients, identified predictors having occult, advanced disease to inform selection patients active surveillance.We studied 10,273 in SEER database diagnosed with (cT1c/T2a, prostate specific antigen less than 10 ng/ml, Gleason 3 + = 6) 2010 2011 treated prostatectomy. The primary outcome was score 7-10 or T3-T4/N1 disease. Multivariable logistic regression cases complete biopsy data...
Background We sought to determine the extent which US Preventive Services Task Force (USPSTF) 2012 Grade D recommendations against prostate‐specific antigen screening may have impacted recent prostate cancer disease incidence patterns in United States across stage, National Comprehensive Cancer Network (NCCN) risk groups, and age groups. Methods SEER*Stat version 8.3.4 was used calculate annual rates from 2010 2015 for men aged ≥50 years according American Joint Committee on stage at...
Despite advances in diagnosis, management and critical care of patients with peritonitis due to hollow viscus perforation, prognosis remains poor. Early assessment by scoring systems will influence the prognosis.Evaluation Mannheim Peritonitis Index (MPI) score for predicting outcome peritonitis.Prospective study 50 admitted operated JSS Medical College Hospital. The structured system i.e. MPI was applied along other clinical biochemical parameters recorded pre-structured proforma. Data...
Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about responsiveness of metastatic PCa to androgen-deprivation therapy (ADT) among races.
PurposeAlthough the association between higher hospital volume and improved outcomes has been well-documented in surgery, there is little data about whether this effect exists for radiation-treated patients. We investigated treatment at a radiation facility that treats high of prostate cancer patients associated with survival men high-risk cancer.Methods MaterialsWe used National Cancer Database (NCDB) to identity diagnosed from 2004 2006. The case (RCV) each was based on its number...
To determine whether patients with Gleason score 5 + 3 = 8 prostate cancer have outcomes more similar to other disease or 9 disease.The Surveillance, Epidemiology and End Results (SEER) database was used study 40 533 men diagnosed N0M0 from 2004 2011. Using 4 as the referent, Fine Gray competing risks regression analyses modelled association between cancer-specific mortality (PCSM).The 5-year PCSM rates for 8, were 6.3%, 6.6%, 13.5%, 13.9%, respectively (P < 0.001). Patients had up a...
PURPOSE: We identified (1) differences in localized prostate cancer (PCa) risk group at presentation and (2) disparities access to initial treatment for Asian American, Native Hawaiian, Pacific Islander (AANHPI) men with PCa after controlling sociodemographic factors. METHODS: assessed all patients the National Cancer Database low-, intermediate-, high-risk disease who as Thai, White, Indian, Chinese, Vietnamese, Korean, Japanese, Filipino, Islander, Laotian, Pakistani, Kampuchean, Hmong....
PurposeTo define and validate a classification of favorable high-risk prostate cancer that could be used to personalize therapy, given consensus guidelines recommend similar treatments for all radiation-managed patients with disease.Methods MaterialsWe studied 3618 cT1-T3aN0M0 or unfavorable intermediate-risk adenocarcinoma treated radiation at single institution between 1997 2013. Favorable was defined as T1c disease either Gleason 4 + = 8 prostate-specific antigen <10 ng/mL 6 >20 ng/mL....
Compared with conventional external-beam radiation therapy (cEBRT) for patients breast cancer (BC) and prostate (PC), shorter regimens may be associated lower treatment noncompletion rates. We assess disparities in receipt of BC PC.
Background: Although the Patient Protection and Affordable Care Act (ACA) has been associated with increased Medicaid coverage among prostate cancer patients, association between expansion risk group at diagnosis, time to treatment initiation (TTI), refusal of locoregional (LT) patients requires further exploration. Methods: Using National Cancer Database, we performed a retrospective cohort analysis all aged 40 64 years diagnosed localized from 2011 2016. Difference-in-difference (DID) was...
Background Certain patients with intermediate‐risk prostate cancer (PCa) may be appropriate candidates for active surveillance (AS). In the current study, authors sought to characterize AS use and early mortality outcomes PCa in United States. Methods The novel Surveillance, Epidemiology, End Results Active Surveillance/Watchful Waiting database identified 52,940 men diagnosed National Comprehensive Cancer Network (cT2b‐c, Gleason score of 7, or a prostate‐specific antigen level 10‐20 ng/mL)...
BACKGROUND Most major cancer organizations seek to reduce sociodemographic disparities in high‐risk cancers partly by increasing access theoretically high‐quality, academic‐oriented care. The objective of this study was determine whether academic centers have less treatment than community using prostate as a test case. METHODS National Cancer Data Base used identify 138,019 patients who were diagnosed with nonmetastatic, from 2004 2012. Multivariable logistic analysis independent...
It remains controversial whether external beam radiation therapy with a brachytherapy boost provides oncologic outcomes equivalent to those of radical prostatectomy or without adjuvant in men Gleason 9-10 prostate cancer. We compared plus for cancer terms overall survival and specific mortality 2 large national databases.Using the NCDB (National Cancer Database) SEER (Surveillance, Epidemiology, End Results) database, we identified 4,367 2,276 patients, respectively, diagnosed clinical...
Abstract Objective To estimate contemporary population‐based patterns of the relative burden prostate cancer‐specific mortality (PCSM) attributable to each N0M0 cancer risk‐group, that may guide prioritization in research, trial design, and clinical practice. Methods We categorized 2004‐2015 Surveillance, Epidemiology, End Results database patients by risk group (low, favorable intermediate, unfavorable high, very highrisk). Using Fine‐Gray method, we calculated 10‐year PCSM group. Among N =...